Share |

Content about Poxviruses

August 14, 2015

Fresh off winning a $20 million Ebola treatment contract from the Department of Health and Human Services, Gaithersburg, Md.-based Emergent BioSolutions (NYSE: EBS) has been awarded another contract, this time from Centers for Disease Control and Prevention (CDC).

The biodefense company announced that the CDC has exercised an option to increase its supply of Vaccinia Immune Globulin (VIGIV), a smallpox vaccine.

December 19, 2011

Biodefense firm, PharmAthene, Inc. (NYSE Amex: PIP) announced that the Delaware Court of Chancery has denied competitor SIGA Technologies an appeal to the Court's decision on September 22, 2011.

With that ruling PharmAthene will receive 50 percent of net profits from the sale of ST-246, a smallpox antiviral drug being sold by SIGA. PharmAthene will receive the profits for 10 years after the first $40 million is accrued by SIGA. In addition, SIGA will pay one-third of attorney fees and witness costs.